مقایسه اثر نالترکسون با یا بدون افزودن فلوکستین در پیشگیری از عود اعتیاد به مواد افیونی

1. Shahraki G, Sedaghat Z, Fararouei M. Family and social predictors of substance use disorder in Iran: A case-control study. Subst Abuse Treat Prev Policy 2019; 14(1): 17.
2. Akbari H, Roshanpajouh M, Nourijelyani K, Mansournia MA, Rahimi-Movaghar A, Yazdani K. Profile of drug users in the residential treatment centers of Tehran, Iran. Health Promot Perspect 2019; 9(3): 248-54.
3. Gholami J, Baheshmat S, Rostam‐Abadi Y, Hamzehzadeh M, Mojtabai R, Rahimi‐Movaghar A, Amin‐Esmaeili M. Mortality and negative outcomes of opioid use and opioid use disorder: A 6‐year follow‐up study. Addiction 2022; 117(7): 2059-66.
4. National Institute on Drug Abuse. Overdose death rates. [cited 2021 Aug 1]. Available from: https://www.drugabuse.gov/drug-topics/trends-statistics/overdose-death-rates
5. Robert M, Jouanjus E, Khouri C, Sam-Lai NF, Revol B. The opioid epidemic: A worldwide exploratory study using the WHO pharmacovigilance database. Addiction 2023; 118: 771-5.
6. Haghighi M, Alizadeh F, Rezaei T, Rezakhani Moghaddam H, Sodaei Zenoozagh H, Mohammadpoorasl A. Environmental and personal factors associated with addiction relapse in referral patients to Marand treatment centers. J Community Health Res 2018; 7: 63-
7. Kleber HD. Pharmacologic treatments for opioid dependence: detoxification and maintenance options. Dialogues Clin Neurosci 2007; 9(4): 455-70.
8. Pergolizzi JV, Raffa RB, Rosenblatt MH. Opioid withdrawal symptoms, a consequence of chronic opioid use and opioid use disorder: Current understanding and approaches to management. J Clin Pharm Ther 2020; 45: 892-903.
9. Rao R. The journey of opioid substitution therapy in India: Achievements and challenges. Indian J Psychiatry 2017; 59: 39-45.

10.                Perez-Macia V, Martinez-Cortes M, Mesones J, Segura-Trepichio M, Garcia-Fernandez L. Monitoring and improving naltrexone adherence in patients with substance use disorder. Patient Prefer Adherence 2021: 999-1015.

11. Brewer C. Optimizing patient care using naltrexone for opioid use disorders. In: Handbook on optimizing patient care in psychiatry. New York: Routledge; 2022: 300-316.
12. Sidana A. Oral naltrexone in opioid dependence syndrome: Revisiting acceptance and effectiveness for relapse prevention. Delhi psychiatry journal 2020; 23(2): 302-6.
13. Smyth BP, Barry J, Keenan E, Ducray K. Lapse and relapse following inpatient treatment of opiate dependence. Ir Med J 2010; 103: 176-9.
14. Tucker TK, Ritter AJ, Maher C, Jackson H. Naltrexone maintenance for heroin dependence: uptake, attrition and retention. Drug Alcohol Rev 2004; 23: 299-309.
15. Xu KY, Mintz CM, Presnall N, Bierut LJ, Grucza RA. Association of bupropion, naltrexone, and opioid agonist treatment with stimulant-related admissions among people with opioid use disorder: A case-crossover analysis. J Clin Psychiatry 2022; 83(4): 41504.
16. Fluyau D, Mitra P, Jain A, Kailasam VK, Pierre CG. Selective serotonin reuptake inhibitors in the treatment of depression, anxiety, and post-traumatic stress disorder in substance use disorders: a Bayesian meta-analysis. Eur J Clin Pharmacol 2022; 78(6): 931-42.
17. Laux, G. Serotonin reuptake inhibitors: citalopram, escitalopram, fluoxetine, fluvoxamine, paroxetine, and sertraline. In NeuroPsychopharmacotherapy. Cham: Springer International Publishing; 2021: 1-13.
18. Sagahón‐Azúa J, Medellín‐Garibay SE, Chávez‐Castillo CE, González‐Salinas CG, Milán‐Segovia RDC, Romano‐Moreno S. Factors associated with fluoxetine and norfluoxetine plasma concentrations and clinical response in Mexican patients with mental disorders. Pharmacol Res Perspect 2021; 9(5): e00864.‏‏
19. Tollefson GD, Rampey AH, Potvin JH, Jenike MA, Rush AJ, Dominguez RA, et al. A multicenter investigation of fixed-dose fluoxetine in the treatment of obsessive-compulsive disorder. In: Obsessive-compulsive disorder and Tourette's syndrome. England, Oxfordshire: Routledge; 2022: 237-45.‏
20. Krupitsky EM, Zvartau EE, Masalov DV, Tsoy MV, Burakov AM, Egorova VY, et al. Naltrexone with or without fluoxetine for preventing relapse to heroin addiction in St. Petersburg, Russia. J Subst Abuse Treat 2006; 31(4): 319-28.‏
21. Krupitsky E, Zvartau E, Masalov D, Tsoi M, Egorova V, Burakov A, et al. A double-blind, placebo controlled trial of naltrexone and fluoxetine for heroin addiction treatment. Eur Neuropsychopharmacology 2005; 15: S284.‏
22. Krupitskiĭ EM, Zvartau EE, Tsoĭ-Podosenin MV, Masalov DV, Burakov AM, Egorova VIu, et al. [Naltrexone and fluoxetine for maintenance of remission in patients with heroin addiction: A double-blind randomized placebo-controlled trial]. Zh Nevrol Psikhiatr Im S S Korsakova 2010; 110(5 pt 2): 44-54. (Russian)
23. Winstanley EL, Bigelow GE, Silverman K, Johnson RE, Strain EC. A randomized controlled trial of fluoxetine in the treatment of cocaine dependence among methadone-maintained patients. J Subst Abuse Treat 2011; 40(3): 255-64.